NXL Overview

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Wall Street analysts forecast NXL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXL is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nexalin Technology Inc revenue for the last quarter amounts to 171.90K USD, increased 532.46

Nexalin Technology Inc. EPS for the last quarter amounts to -0.13 USD, decreased -50.00

Nexalin Technology Inc (NXL) has 8 emplpoyees as of April 03 2026.

Today NXL has the market capitalization of 7.24M USD.